Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
SP-420 by Abfero Pharmaceuticals for Beta Thalassaemia: Likelihood of Approval
SP-420 is under clinical development by Abfero Pharmaceuticals and currently in Phase II for Beta Thalassaemia. According to GlobalData, Phase...